Advice
following a full submission:
finerenone (Kerendia®) is accepted for use within NHSScotland.
Indication under review: for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
In a randomised, double-blind, phase III study, the addition of finerenone to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker reduced the risk of the primary composite renal outcome comprising kidney failure, a sustained decrease in estimated glomerular filtration rate of ≥40% or death from renal causes compared with placebo.
Download detailed advice783KB (PDF)
Medicine details
- Medicine name:
- finerenone (Kerendia)
- SMC ID:
- SMC2486
- Indication:
Treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
- Pharmaceutical company
- Bayer Plc
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 November 2022